Time to Euromit 2023


For inquiries about sponsorships with Euromit 2023 please visit our Become a sponsor page or contact: sponsor@euromit2023.eu


Diamond Sponsor

About Reneo Pharmaceuticals

Reneo is a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Our lead product candidate, REN001, is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ). REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation, and may increase production of new mitochondria.

For additional information, please see reneopharma.com.


Diamond Sponsor

For over 30 years, Oroboros Instruments has been delivering the O2k-technology for mitochondria, bioenergetics, and cell research. The NextGen-O2k is a complete experimental system for high-resolution fluorespirometry, redox biology and PhotoBiology. It enables simultaneous monitoring of oxygen consumption together with either coenzyme Q redox state, NAD(P)H redox state, cyclic voltammetry, H2O2 production (AmR), mt-membrane potential (TMRM, Safranin and Rhodamine 123), Ca2+ uptake capacity (CaG), ATP production (MgG) or photobiology measurements. The O2k-technology facilitates the study of mitochondrial function in cancer, diabetes, aging, neurodegeneration, exercise physiology and mitochondrial medicine.


Diamond Sponsor

GenSight Biologics is the first European biopharma and tech company to develop and combine gene therapy with pioneering technology in order to create and give access to new therapeutic solutions for patients with severe ophthalmic diseases.

Created 10 years ago, GenSight Biologics is the result of a unique partnership between academic research and entrepreneurship. We combine the advantages of a biotech with those of a pharmaceutical company.

We have a singular focus: provide access to treatments for patients suffering from vision loss. Our therapeutic area is serious degenerative diseases of the eye and central nervous system. Our approach is to pave the way to bring breakthrough therapies to patients.

We are present at the major stages of gene therapy and technological innovation. We develop, test, produce and market therapeutic approaches supported by our two proprietary technology platforms: Mitochondrial Targeting Sequence, or MTS, and optogenetics. Our biologic compound is capable of restoring cellular functions altered by a rare mitochondrial disease in the heart of the retina. Separately, we leverage optogenetics, which harnesses the latest science, combining optics and genetics, to amplify light stimulation on neuronal cells, resulting in partial restoration of sight.


Gold Sponsor

Abliva – Delivering mitochondrial health

Abliva discovers and develops medicines for the treatment of mitochondrial diseases. These rare and often very severe diseases occur when the cell’s energy provider, the mitochondria, does not function properly. The company has prioritized two projects. KL1333, a powerful regulator of the essential co-enzymes NAD⁺ and NADH, has entered late-stage development. NV354, an energy replacement therapy, has completed preclinical development. Abliva is based in Lund, Sweden. www.abliva.com

Pretzel Therapeutics

Gold Sponsor

About Pretzel Therapeutics

Pretzel Therapeutics is a biotechnology company harnessing the intricacies of mitochondrial biology to develop groundbreaking therapies. Pretzel was founded by leading academic experts in mitochondrial biology and is backed by a world-class investor syndicate. The company is headquartered in Waltham, MA and has research facilities in Gothenburg, Sweden. For more information, visit www.pretzeltx.com.


Gold Sponsor

UCB is a global biopharmaceutical company focused on severe diseases that have significant unmet needs. By putting patients at the center of everything we do, we strive to enable people to live their best lives, delivering impactful solutions that patients value.


Silver Sponsor

OMEICOS Therapeutics

Bronze Sponsor

About OMEICOS Therapeutics

OMEICOS is a clinical-stage biopharmaceutical company and has discovered a series of metabolically robust synthetic analogues of omega-3 fatty acid-derived compounds that have the potential to treat mitochondrial dysfunction and inflammation in patients with cardiovascular and other diseases.

Our clinical lead compound OMT-28 has shown an excellent safety profile in two clinical trials and 162 individuals in total and profound effects on key biomarkers of metabolic and inflammatory stress such as GDF-15, IL-6, PTX-3 and hs-CRP.

OMEICOS plans for a proof-of-concept clinical study with OMT-28 in patients with Primary Mitochondrial Diseases with myopathy/cardiomyopathy. The trial will be initiated in H1/2024.

For additional information, please visit our web page www.omeicos.com


Copan is dedicated to developing high-quality and cutting-edge sample collection products for infectious diseases, human genomics, environmental and forensic applications, along with automated workflow solutions.

Our ideas drove 40 years of progress in preanalytics, resulting in meaningful products tailored to fit any need. Among them, FLOQ technology revolutionized sample collection, while WASPLab® advanced hardware and A.I. modules leveraged automation and digitalization to redefine full lab automation.

Copan’s Workflow-Integrated System Environment can accompany your biological samples from the collection to impeccable diagnostics, unlocking your lab’s real potential and improving treatment indication and patient care.